small molecule

TEKTURNA HCT

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

Loss of exclusivityJuly 2028latest FDA-listed patent expiry
CompanyNODEN PHARMA DAC

Drug detail

Brand nameTEKTURNA HCT
Active ingredientALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE
StrengthEQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2008
Marketing statusDISCN

Listed patents

PatentExpiresType
8618172July 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TEKTURNA HCT patent cliff — loss of exclusivity July 2028 | CliffBio